Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.
about
Biomarkers and surrogate endpointsThe 5-HT 4 receptor levels in hippocampus correlates inversely with memory test performance in humansFunctional biomarkers for the acute effects of alcohol on the central nervous system in healthy volunteers.Surrogate outcomes in neurology, psychiatry, and psychopharmacologyAn open-source hardware and software system for acquisition and real-time processing of electrophysiology during high field MRI.Do antidepressants cure or create abnormal brain states?Increased Force Variability Is Associated with Altered Modulation of the Motorneuron Pool Activity in Autism Spectrum Disorder (ASD).A preliminary study of the neural mechanisms of frustration in pediatric bipolar disorder using magnetoencephalography.Healthy individuals treated with clomipramine: an fMRI study of brain activity during autobiographical recall of emotions.The psychoactive effects of psychiatric medication: the elephant in the room.ASD: Psychopharmacologic Treatments and Neurophysiologic Underpinnings.Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats.Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron.Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.Patients with borderline personality disorder and major depressive disorder are not distinguishable by their neuropsychological performance: a case-control study.How do psychiatric drugs work?Quantitative EEG abnormalities are associated with memory impairment in recently abstinent methamphetamine-dependent individuals.Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder.A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers.Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.Resting-state oscillatory activity in autism spectrum disorders.Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's diseaseBiomarkers for the effects of cannabis and THC in healthy volunteers.Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors.The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review.Guidelines for the recording and evaluation of pharmaco-sleep studies in man: the International Pharmaco-EEG Society (IPEG).Decreased delta sleep ratio and elevated alpha power predict vulnerability to depression during interferon-alpha treatment.Emotion stimulus processing in narcolepsy with cataplexy.The 5-hydroxytryptamine4 receptor enables differentiation of informational content and encoding in the hippocampus.Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation.Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment.Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.Against the stream: Antidepressants are not antidepressants - an alternative approach to drug action and implications for the use of antidepressants.EEG marker of inhibitory brain activity correlates with resting-state cerebral blood flow in the reward system in major depression.A single dose of antidepressant alters eye-gaze patterns across face stimuli in healthy women.Pharmacodynamic response profiles of anxiolytic and sedative drugs.Selective deficit in executive functioning among patients with borderline personality disorder.
P2860
Q24678760-E9D8707F-5136-4700-98AE-D7B10DE59EF4Q27982082-85FAC625-4FA2-481A-AF0C-611B7E55EE1FQ30469906-6E2319A6-9C70-41B6-9731-F7706AFBA37EQ30473416-2B587977-1D80-41F9-BC07-8FC2FDF7728CQ30482018-1975320C-2557-41FF-989F-F51F4D0B0DF0Q33244689-ED159472-3182-4099-968F-AC60919032DFQ33624274-B2B8FB75-76A3-4C63-8A10-7DA55F1461C0Q33737402-FF6A038B-B24A-4071-9182-B06BA4D5FB09Q33840518-B9CD8429-43F4-40A5-AB88-0FBE8BD79042Q33989385-76F75D95-7672-45F9-B592-C07595E247BEQ34270618-46EF6BA3-7D49-483B-9E27-39D696580DD9Q34559591-099F9CFB-AA1E-439E-A1DD-D65F09671232Q34811394-7E010DB9-A215-4AF7-B879-4209C18D1CADQ34996934-50EDCBC9-A2E0-4C5F-9D8C-3A577E804036Q35062665-AAFC22E2-E108-4030-862E-C4FC576F465DQ35591334-C64B7D3E-6593-45AE-85EA-914402766A75Q35954607-7E48F3AE-35DB-44D7-B35B-9D2553BE1F2EQ36148702-936CF187-F808-449D-B8FA-54C473BF037CQ36410788-F422462F-42D4-40AE-ADEF-88B0F518B3BEQ36685572-4C7FA1B7-2D9B-4295-A855-3EF214D5B723Q36800845-A4FB4E5B-B8ED-4605-886A-CCD4D29FA1DEQ37129750-9821E86B-0078-4993-943B-829E014DBEC8Q37156258-D51E3109-268A-40F2-BE5E-34293618A0C0Q37669003-769BDD58-144E-46AA-BF9B-08CCA090B156Q37678438-D0ED1C68-DEF4-40F9-B63B-73EE6B5C1352Q38095247-D9E2E5CD-90EE-4C03-AE43-4F0FE5BA72ECQ39271208-3D18CD1E-7363-415C-A249-2F4CA2CA5C8AQ39491116-B1B00DDF-8AF3-4F35-B3DA-EEF0EFC7EC64Q40072497-7DBE4B79-CE37-4BBE-8436-D8EEC82ADCF5Q40086970-5FB978C7-2A21-4BAB-88B4-F5DFC7F6539AQ40810950-6248806B-70BE-4080-9CC5-8DFEAB520534Q44254954-E30A7936-B83B-4621-B732-850B4D0F5CCFQ45251058-C71C858D-B97C-4B3E-974C-057636255336Q46404900-CF703C13-7EBE-4F27-86DD-893933013E72Q47549963-D7C1ECA7-52D3-49E8-95B1-F026A7310BF0Q47594451-E7E65ED8-2192-44A8-80BF-122162796576Q47819021-79DADB88-D88E-4C61-9500-7DF82EB093D5Q48178645-CED2A039-8554-4AAE-A3B2-5CCD28B37BD2Q51958420-8D12D3E8-5F2A-4207-B88B-271ED939A852
P2860
Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Biomarkers for the effects of ...... s (SSRIs) in healthy subjects.
@ast
Biomarkers for the effects of ...... s (SSRIs) in healthy subjects.
@en
type
label
Biomarkers for the effects of ...... s (SSRIs) in healthy subjects.
@ast
Biomarkers for the effects of ...... s (SSRIs) in healthy subjects.
@en
prefLabel
Biomarkers for the effects of ...... s (SSRIs) in healthy subjects.
@ast
Biomarkers for the effects of ...... s (SSRIs) in healthy subjects.
@en
P2093
P2860
P1476
Biomarkers for the effects of ...... s (SSRIs) in healthy subjects.
@en
P2093
Biomarker Working Group of the German Association for Applied Human Pharmacology
G J H Dumont
J M A van Gerven
S J de Visser
P2860
P304
P356
10.1111/J.1365-2125.2005.02342.X
P407
P577
2005-05-01T00:00:00Z